Bausch & Lomb Canada Introduces PrLotemax™ and PrAlrex®
TORONTO — Lotemax™ (loteprednol etabonate 0.5%) and Alrex® (loteprednol etabonate 0.2%) are now available by prescription in Canada. Canadians can now benefit from the proven efficacy and safety record of these two unique ocular steroids used by millions of patients for over 10 years.1
Lotemax, indicated for the treatment of post-operative inflammation following cataract surgery, is the number one branded ocular steroid in the U.S. Alrex is indicated for temporary, short-term relief of the signs and symptoms of seasonal allergic conjunctivitis (SAC).
Both Lotemax and Alrex are based on the loteprednol etabonate molecule, which is an ester-based molecule. It is structurally similar to other corticosteroids, however, the number 20 position ketone is replaced with an ester group, which in turn gives both products unique properties and benefits.
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.